HIMS (Hims & Hers Health) Piotroski F-Score: 4 (As of Jun. 25, 2026) — 20% Below Median


HIMS Hims & Hers Health Inc HIMS
81 GF Score
Price $32.70
GF Value $38.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Hims & Hers Health Piotroski F-Score?

Hims & Hers Health HIMS -0.79% 81 Piotroski F-Score is 4 as of Jun. 25, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates HIMS with a GF Score™ of 81/100 and a GF Value™ of $38.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 981 Drug Manufacturers companies, Hims & Hers Health ranks worse than 60.86% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hims & Hers Health has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Hims & Hers Health's Piotroski F-Score or its related term are showing as below:

HIMS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 6
Current: 4

During the past 7 years, the highest Piotroski F-Score of Hims & Hers Health was 6. The lowest was 2. And the median was 5.

Hims & Hers Health  (NYSE:HIMS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hims & Hers Health Piotroski F-Score Related Terms


Hims & Hers Health Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Hims & Hers Health's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hims & Hers Health Piotroski F-Score Chart

Hims & Hers Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 3.00 5.00 5.00 6.00 4.00

Hims & Hers Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 4.00 4.00 4.00

HIMS vs LNTH, LQDA, ALKS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hims & Hers Health Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hims & Hers Health's Piotroski F-Score falls into.


HIMS
81GF Score
Hims & Hers Health Inc HIMS
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 42.505 + 15.774 + 20.601 + -92.115 = $-13 Mil.
Cash Flow from Operations was -19.117 + 148.721 + 61.312 + 89.356 = $280 Mil.
Revenue was 544.833 + 598.976 + 617.818 + 608.104 = $2,370 Mil.
Gross Profit was 416.196 + 442.058 + 444.435 + 396.787 = $1,699 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(891.711 + 1877.582 + 2233.304 + 2154.705 + 2267.043) / 5 = $1884.869 Mil.
Total Assets at the begining of this year (Mar25) was $892 Mil.
Long-Term Debt & Capital Lease Obligation was $1,126 Mil.
Total Current Assets was $1,045 Mil.
Total Current Liabilities was $619 Mil.
Net Income was 13.297 + 75.588 + 26.025 + 49.485 = $164 Mil.

Revenue was 315.648 + 401.556 + 481.139 + 586.01 = $1,784 Mil.
Gross Profit was 256.613 + 317.886 + 369.541 + 430.689 = $1,375 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(448.106 + 480.5 + 602.261 + 707.539 + 891.711) / 5 = $626.0234 Mil.
Total Assets at the begining of last year (Mar24) was $448 Mil.
Long-Term Debt & Capital Lease Obligation was $60 Mil.
Total Current Assets was $447 Mil.
Total Current Liabilities was $280 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hims & Hers Health's current Net Income (TTM) was -13. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hims & Hers Health's current Cash Flow from Operations (TTM) was 280. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-13.235/891.711
=-0.01484225

ROA (Last Year)=Net Income/Total Assets (Mar24)
=164.395/448.106
=0.36686632

Hims & Hers Health's return on assets of this year was -0.01484225. Hims & Hers Health's return on assets of last year was 0.36686632. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hims & Hers Health's current Net Income (TTM) was -13. Hims & Hers Health's current Cash Flow from Operations (TTM) was 280. ==> 280 > -13 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1126.458/1884.869
=0.59763198

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=59.648/626.0234
=0.09528078

Hims & Hers Health's gearing of this year was 0.59763198. Hims & Hers Health's gearing of last year was 0.09528078. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1045.363/618.777
=1.68940184

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=446.964/280.362
=1.59423888

Hims & Hers Health's current ratio of this year was 1.68940184. Hims & Hers Health's current ratio of last year was 1.59423888. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hims & Hers Health's number of shares in issue this year was 228.357. Hims & Hers Health's number of shares in issue last year was 246.61. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1699.476/2369.731
=0.71715988

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1374.729/1784.353
=0.77043556

Hims & Hers Health's gross margin of this year was 0.71715988. Hims & Hers Health's gross margin of last year was 0.77043556. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=2369.731/891.711
=2.65751011

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1784.353/448.106
=3.98198864

Hims & Hers Health's asset turnover of this year was 2.65751011. Hims & Hers Health's asset turnover of last year was 3.98198864. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hims & Hers Health has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Hims & Hers Health (HIMS) has a Piotroski F-Score of 4 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Hims & Hers Health and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Hims & Hers Health's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Hims & Hers Health ranks #597 out of 981 companies in the Drug Manufacturers industry, placing it in the top 60.9%.
Is Hims & Hers Health's Piotroski F-Score too high?
Hims & Hers Health's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Hims & Hers Health's value of 4 is 20% below this industry median. Based on the distribution chart, Hims & Hers Health ranks #597 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hims & Hers Health has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's Piotroski F-Score compare to LNTH and LQDA?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #597 out of 981 companies for Piotroski F-Score. This places Hims & Hers Health in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Hims & Hers Health's value of 4 is 20% below this benchmark. Historically, Hims & Hers Health's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Hims & Hers Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hims & Hers Health's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Hims & Hers Health and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (HIMS) is currently considered Modestly Undervalued. The stock's GF Value™ is $38.61, compared to a current price of $32.70 — trading 15.3% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Drug Manufacturers industry median of 5.00. Hims & Hers Health's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Hims & Hers Health (HIMS), the current Piotroski F-Score is 4 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hims & Hers Health (HIMS) Overvalued in 2026?

Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued. The current stock price of $32.70 is trading 15.3% below its estimated GF Value™ of $38.61. GuruFocus considers Hims & Hers Health to be Modestly Undervalued.

Key valuation signals for HIMS:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: $38.61 vs. price of $32.70 (15.3% below fair value)
  • GF Score™: 81/100 with 3 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#597 of 981)

No single metric tells the full story. See the HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hims & Hers Health Business Description

Other Exchanges HIMS:Mexico82W:Germany
Address 2269 Chestnut Street, No. 523, San Francisco, CA, USA, 94123
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
81GF Score

Get the complete analysis for HIMS

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.70
Price
$38.61
GF Value